Dermtech signs a commercial & medicare advantage coverage agreement
Category: #health  By Mateen Dalal  Date: 2020-01-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dermtech signs a commercial & medicare advantage coverage agreement

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detection of melanoma available to the regional health plan’s Medicare Advantage and commercial members.

This agreement marks the health plan’s first contract that would offer coverage for PLA. Apparently, DermTech’s pigmented lesion assay comes as the first-ever, non-invasive gene expression test that detects melanoma at an early stage. PLA holds a 99% negative predictive value, which means that the possibility of the PLA missing a melanoma is under 1% when administered correctly.

Speaking on the development, Dan Visage, Senior Vice President of Payor Access, Dermtech, said that the company is thrilled to reveal that its test is currently accessible by a segment of medicare advantage and commercial members.

Payor Access’ PLA test delivers substantial benefits in early melanoma identification and condensed biopsies of benign lesions. These tests would lower the cost to the healthcare system, cites Visage.

Prior to this news, Dermtech had made headlines when it expanded its intellectual property by issuing the patent US10,407,729. This patent published by the US Patent Office was labeled “Diagnosis of melanoma by nucleic acid analysis” and involved claims in association with the firm’s technology to non-invasively attain genomic evidence for illustrating skin lesions 

As per Dr. Zuxu Yao, Chief Scientific Officer, DermTech, this patent highlights their firm’s ability to non-invasively achieve significant genomic data and expands its previous work. DermTech’s technology offers actionable genomic information that can’t be visually determined.

Providing data on crucial targets like PRAME without the help of surgical biopsies, holds the potential to augment the dermatology practice, claims Dr. Yao.

Source Credit: https://investors.dermtech.com/news-releases/news-release-details/dermtech-enters-commercial-and-medicare-advantage-payor-coverage

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
By Mateen Dalal

DealerSocket, a customer relationship management solutions provider, has recently completed the acquisition of DMS provider Auto/Mate to offer an all-in-one innovative software for their dealerships. Auto/Mate is a leading company that develops and m...

EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
By Mateen Dalal

The European Union and the United States are likely to partner to counter the increasing dominance of Chinese tech giant, Huawei Technologies on next generation 5G telecommunications technology. However, this partnership will reportedly only come int...

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
By Mateen Dalal

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various...